Title
High-throughput single-cell activity-based screening and sequencing of antibodies using droplet microfluidics
Date Issued
01 June 2020
Access level
open access
Resource Type
journal article
Author(s)
Gérard A.
Woolfe A.
Mottet G.
Reichen M.
Castrillon C.
Menrath V.
Ellouze S.
Poitou A.
Doineau R.
Briseno-Roa L.
Canales-Herrerias P.
Mary P.
Rose G.
Ortega C.
Delincé M.
Essono S.
Jia B.
Iannascoli B.
Richard-Le Goff O.
Kumar R.
Stewart S.N.
Pousse Y.
Shen B.
Grosselin K.
Saudemont B.
Sautel-Caillé A.
Godina A.
McNamara S.
Eyer K.
Millot G.A.
Baudry J.
England P.
Nizak C.
Jensen A.
Griffiths A.D.
Bruhns P.
Brenan C.
Publisher(s)
Nature Research
Abstract
Mining the antibody repertoire of plasma cells and plasmablasts could enable the discovery of useful antibodies for therapeutic or research purposes1. We present a method for high-throughput, single-cell screening of IgG-secreting primary cells to characterize antibody binding to soluble and membrane-bound antigens. CelliGO is a droplet microfluidics system that combines high-throughput screening for IgG activity, using fluorescence-based in-droplet single-cell bioassays2, with sequencing of paired antibody V genes, using in-droplet single-cell barcoded reverse transcription. We analyzed IgG repertoire diversity, clonal expansion and somatic hypermutation in cells from mice immunized with a vaccine target, a multifunctional enzyme or a membrane-bound cancer target. Immunization with these antigens yielded 100–1,000 IgG sequences per mouse. We generated 77 recombinant antibodies from the identified sequences and found that 93% recognized the soluble antigen and 14% the membrane antigen. The platform also allowed recovery of ~450–900 IgG sequences from ~2,200 IgG-secreting activated human memory B cells, activated ex vivo, demonstrating its versatility.
Start page
715
End page
721
Volume
38
Issue
6
Language
English
OCDE Knowledge area
Biotecnología relacionada con la salud
Scopus EID
2-s2.0-85082931161
PubMed ID
Source
Nature Biotechnology
ISSN of the container
10870156
Sponsor(s)
Funding text 1 We would like to thank M. Holsti and W. Somers (Pfizer, BioMedicine Design) for advice on the technology development and critical reading of the manuscript; R. Nicol (Whitehead Institute, MIT Center for Genome Research) for advice on barcoded sequencing; at the Institut Pasteur, H. Mouquet for advice on antibody sequence selection, and F. Jönsson for advice on flow cytometry analysis; T. Kirk and S. Foulon (ESPCI Paris) for their help developing the barcoded hydrogel beads; S. N. Stewart (HiFiBio Therapeutics Inc.) for her help producing and analysing recombinant antibodies; the Institut Pierre-Gilles de Gennes (IPGG) for use of clean room facilities and the laser engraver (CII08, Axyslaser). This work was supported by the French Agence Nationale de la Recherche (ANR-14-CE16-0011 project DROPmAbs), by the Centre d’Innovation et Recherche Technologique (Citech) through the Institut Carnot Pasteur Microbes & Santé (ANR 16 CARN 0023-01), by BPI France (OSIRIS and CELLIGO projects) and by the French ‘Investissements d’Avenir’ program via the CELLIGO project and grant agreements ANR-10-NANO-02, ANR-10-IDEX-0001-02 PSL, ANR-10-LABX-31 and ANR-10-EQPX-34. NGS was performed by the ICGex NGS platform of the Institut Curie and the Institut de Biologie Intégrative de la Cellule (I2BC) platform (Gif-sur-Yvette) supported by the grants ANR-10-EQPX-03 and ANR-10-INBS-09-08 (France Génomique Consortium), by the Canceropole Ile-de-France and by the SiRIC-Curie program (SiRIC Grant INCa-DGOS-4654). C.C. acknowledges financial support from CONCYTEC, Peru. P.C.H. is a scholar in the Pasteur - Paris University (PPU) International PhD program and was also supported by the Fondation pour la Recherche Médicale (FRM; FDT201904008240). K.E. acknowledges financial support from the Swiss National Science Foundation and The Branco Weiss Fellowship - Society in Science. Funding text 2 Experiments using mice were validated by i) the CETEA ethics committee number 89 (Institut Pasteur, Paris, France) under #2013-0103, and by the French Ministry of Research under agreement #00513.02, and ii) the French ethics committee number 80 (CellVax) under reference APAFIS#6063-2016071213009170 v5.
Sources of information: Directorio de Producción Científica Scopus